论文部分内容阅读
目的:检测非小细胞肺癌(NSCLC)中转化生长因子βⅡ型受体(TGFBR2)的表达,并探讨其表达的变化与NSCLC的发生的相关性及与临床病理因素的关系。方法:采用组织芯片技术和免疫组化方法,检测115对原发性NSCLC(腺癌50例,鳞癌44例,腺鳞癌6例,巨细胞癌2例,大细胞癌13例)及其相应正常对照肺组织中TGFBR2蛋白的表达情况。结果:TGFBR2在NSCLC与正常对照组织中的表达差异有统计学意义(P<0.01),大细胞癌与腺癌、鳞癌等病理类型的表达水平差异有统计学意义(P<0.05),但TGFBR2的表达变化与患者年龄、性别、肿瘤大小和局部侵袭、淋巴结侵袭、转移、临床分期差异无统计学意义(P>0.05)。结论:TGFBR2的表达异常与病理类型有关,TGFBR2的表达下调可能与NSCLC尤其是大细胞癌的发生或发展相关。
OBJECTIVE: To detect the expression of transforming growth factor β receptor (TGFBR2) in non-small cell lung cancer (NSCLC), and to explore the relationship between the expression of TGFBR2 and the occurrence of NSCLC and the clinicopathological factors. Methods: Tissue microarray and immunohistochemistry were used to detect 115 pairs of primary NSCLC (50 adenocarcinoma, 44 squamous cell carcinoma, 6 adenosquamous carcinoma, 2 giant cell carcinoma and 13 large cell carcinoma) Corresponding normal control TGFBR2 protein expression in lung tissue. Results: The expression of TGFBR2 in NSCLC was significantly different from that in normal control (P <0.01). There were significant differences in the expression of TGFBR2 among pathological types of large cell carcinoma, adenocarcinoma and squamous cell carcinoma (P <0.05) There was no significant difference in the expression of TGFBR2 between patients with age, gender, tumor size, local invasion, lymph node invasion, metastasis and clinical stage (P> 0.05). Conclusion: The abnormal expression of TGFBR2 is related to the pathological type. The down-regulation of TGFBR2 may be related to the occurrence and development of NSCLC, especially large cell carcinoma.